Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

25.41 -0.13 (-0.51%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum ↗
Teva beat Q1 EPS estimates and raised 2025 profit guidance as Austedo sales soared and margins improved, despite missing revenue expectations. 
Via Benzinga
News headline image
Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report ↗
Teva stock jumped early Wednesday after the drugmaker hiked its 2025 profit outlook, though trimmed its sales forecast. 
Via Investor's Business Daily
Topics Government
News headline image
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Forecasting The Future: 6 Analyst Projections For Teva Pharmaceutical Indus ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target ↗
Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes. 
Via Benzinga
News headline image
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? ↗
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases. 
Via Benzinga
News headline image
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
What Does the Market Think About Teva Pharmaceutical Indus? ↗
 
Via Benzinga
News headline image
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now ↗
Short-term uncertainty has led to a golden opportunity for long-term investors. 
Via The Motley Fool
Topics Economy Government Stocks
News headline image
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility ↗
Some of Wall Street's most-prominent asset managers were scooping up shares of time-tested businesses before the stock market meltdown. 
Via The Motley Fool
Topics Government Stocks World Trade
News headline image
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
News headline image
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
From Teva Pharmaceutical Industries Ltd; Samsung Bioepis Co., Ltd.
Via GlobeNewswire
News headline image
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now ↗
Via The Motley Fool
News headline image
Teva Releases Q1 2025 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks ↗
Duquesne Family Office's chief is dumping shares of Wall Street's hottest artificial intelligence (AI) stocks in favor of a trio of companies that are righting their respective ships. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings ↗
Via The Motley Fool
News headline image
Is SoundHound AI Stock a Buy Now? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
From Teva Pharmaceutical Industries Ltd; Medincell
Via GlobeNewswire
News headline image
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease ↗
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025. 
Via Benzinga
News headline image
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist ↗
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.